Gyre Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Gyre Therapeutics, Inc. (GYRE) had Available-for-sale Securities, Amortized Cost Basis of $64.53 million as of 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2021-11-12
- 2021-09-30: Available-for-sale Securities, Amortized Cost Basis $64.53M.
- 2021-06-30: Available-for-sale Securities, Amortized Cost Basis $86.52M.
- 2021-03-31: Available-for-sale Securities, Amortized Cost Basis $107.00M.
- 2020-12-31: Available-for-sale Securities, Amortized Cost Basis $81.89M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2021-09-30 | $64.53M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $86.52M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $107.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $81.89M 10-Q · filed 2021-11-12 | |
| 2020-09-30 | $104.05M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $117.32M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $104.39M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $76.83M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $83.65M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $93.44M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $103.77M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $119.06M 10-K · filed 2020-02-20 | |
| 2018-09-30 | $129.16M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $135.73M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $143.67M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $37.64M 10-K · filed 2019-03-08 | $37.64M 10-K · filed 2018-03-19 |
| 2017-09-30 | $33.17M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $37.57M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $27.48M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $36.55M 10-K · filed 2018-03-19 | |
| 2016-09-30 | $49.03M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $54.05M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $57.96M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $66.25M 10-K · filed 2017-03-08 | |
| 2015-09-30 | $72.52M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $22.39M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $33.14M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $1.55M 10-K · filed 2016-03-09 | $54.35M 10-K · filed 2015-03-16 |
| 2014-09-30 | $68.75M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $79.26M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $86.94M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $89.11M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $93.18M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $105.86M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $104.91M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $106.39M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $125.03M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $138.05M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $157.95M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |